Development of bispecific NT-PSMA heterodimer for prostate cancer

Subscriber access provided by UNIV AUTONOMA DE COAHUILA UADEC

Communication

Development of bispecific NT-PSMA heterodimer for prostate cancer imaging: a potential approach to address tumor heterogeneity Xiaofen Ma, Mengzhe Wang, Hui Wang, Tao Zhang, Zhanhong Wu, Mariia Sutton, Vladimir V. Popik, guihua Jiang, and Zi-Bo Li Bioconjugate Chem., Just Accepted Manuscript • DOI: 10.1021/acs.bioconjchem.9b00252 • Publication Date (Web): 29 Apr 2019 Downloaded from http://pubs.acs.org on April 30, 2019

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 20 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Bioconjugate Chemistry

Development of Bispecific NT-PSMA Heterodimer for Prostate Cancer Imaging: a Potential Approach to Address Tumor Heterogeneity Xiaofen Ma#†,‡, Mengzhe Wang#‡, Hui Wang‡, Tao Zhang‡, Zhanhong Wu‡, Mariia V. Sutton§, Vladimir V. Popik§, Guihua Jiang†,*, Zibo Li‡,* †.

Department of Medical Imaging, Guangdong Second Provincial General Hospital, Guangzhou

City, Guangdong Province, 510317, P. R. China ‡.

Biomedical Research Imaging Center, Department of Radiology, University of North Carolina

at Chapel Hill, Chapel Hill, North Carolina, 27599, USA §.

Department of Chemistry, University of Georgia, Athens, Georgia, 30602, USA

# Contributed

equally.

* Correspondence and requests for materials should be addressed to [email protected] or [email protected]

Running title: NT-PSMA PET in Prostate Cancer Keywords: Neurotensin receptor (NTR), Prostate-specific membrane antigen (PSMA), heterodimer, Positron Emission Tomography (PET), Prostate Cancer.

ACS Paragon Plus Environment

Bioconjugate Chemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Abstract Prostate cancer is a heterogeneous disease with poor survival rate at late stage. In this report, a dual targeting PET agent was developed to partially address tumor heterogeneity issue. The heterodimer F-BCN-PSMA-NT was designed to target PSMA and neurotensin receptor1 (NTR1), both of which have demonstrated the great potential in prostate cancer management. The heterodimer was synthesized through the conjugation of Glu-urea-lys(Ahx) (PSMA targeting motif) and NT20.3 (NTR1 targeting motif) to a symmetric trifunctional linker, bearing an azide group for further modification. Radio-labeling was performed using strain promoted azide-alkyne click reaction with high yield. Cell based assays suggested F-BCN-PSMA-NT has comparable or only slightly reduced binding affinity with the corresponding monomers. Small animal PET clearly demonstrated that the heterodimer probe not only has prominent uptake in NTR1 positive/PSMA negative PC-3 tumors (1.4 ± 0.3 %ID/g), but also in the PSMA positive/NTR1 negative LnCap tumors (1.3 ± 0.2 %ID/g). The tracer showed comparable tumor to background ratio with each monomer. In summary, prostate cancer is a heterogeneous disease in need of improved diagnostics and treatments. The PSMA-NT heterodimer represent a new class of molecules that can be used to target two distinct antigens related to prostate cancer. In addition to the imaging applications demonstrated in this study, the agent also holds the great potential on the treatment of heterogeneous prostate cancer.


Page 2 of 20

Page 3 of 20 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Introduction Despite of the recent improvement in prognosis and treatment, prostate cancer remains one of the most common malignancy and leading causes of cancer-related death in the United States and Europe1. Due to its high occurrence rate and low 29% 5-year survival rate at late stage, there is clearly an urgent need to develop new prognostic and therapeutic options2. Prostate cancer is a highly heterogeneous pathology in need of improved diagnostics and therapeutics3. Randomized trials and epidemiological data indicate that the current standard for prostate cancer diagnosis—detection of prostate-specific antigen (PSA) levels—has had little survival benefit for patients and has contributed to widespread overdiagnosis and overtreatment of prostate cancer4. Recently, prostate-specific membrane antigen (PSMA) has become one of the most widely studied prostate cancer biomarkers and has been proved that its expression was associated with progression to androgen independence of prostate cancer 5-8. It was also validated by several methods that increased PSMA expression was found in benign prostatic hyperplasia, high-grade prostatic intraepithelial neoplasia and prostatic adenocarcinoma9. In spite of the reasonable expression in primary prostate tumors, regardless of androgen status, PSMA targeted PET agents was also clinically attractive due to its ability to image recurrent or some metastatic prostate cancer lesions with high contrast and potentially higher sensitivity compared with Choline-PET/CT10-15. However, the limitation of PSMA as biomarker is its low expression in tumor tissues with low Gleason scores, which has been demonstrated by 68Ga-PSMA-11 imaging16, 17. Tumor heterogeneity is another factor that has to be considered in prostate cancer imaging and therapy. In addition to PSMA, G-protein-coupled neurotensin receptor (NTR) and its ligand neurotensin peptide (NT) were recently suggested to play important roles in a variety of cancers, especially prostate cancer18-21. Studies have showed that NTRs affect the signaling on IL-8 expression and subsequent CXCR1/STAT3 signaling pathway activation in malignant tumors and induce gelsolin mediated invasion of cancer cell through NTR1 activation22, 23. Overexpression of NTR has been discovered in androgen-independent human prostate tissues and, thus, provides a potential target for prostate cancer diagnosis and therapy24-26. Additionally, NTR1 was also reported to be expressed in neuroendocrine prostate cancers, in which PSMA expression was low23, 27. Clearly, NTR1 could be another important biomarker that may complement PSMA. Due to the heterogeneity seen in receptor expression in prostate tumors,



Page 4 of 20

targeting more than one receptor may have an advantage over single receptor targeting. In this study, we report the development of a NT-PSMA heterodimer, which was then radiolabeled with 18F

via strain-promoted azide-alkyne reaction (Scheme 1). The targeting efficacy was evaluated

in both androgen-dependent LnCap and androgen-independent PC-3 prostate cancer xenografts and compared with its corresponding NT and PSMA monomers (Scheme 2 and 3). O

O O O

NO

O

O

O

N

O

NH2 H2N NH NH

HN N O O O N

O

O

O

+

N3

O O

O ON

O

OH OH O NH O DMSO, HN

NH HN NH2

+

NH2

O

N

O

O

18

O

O

O

COOH

NH HN NH2

F

+

H

H

HOOCH N N HCOOH H H O

O O

HN

H N

O

O

N

O

O O

O

N

COOH HOOCH N N HCOOH H H

80 C, 15min

N

HN

O

O

18

O H

H

NH H2N NH NH

HN N O O O N

O

o

N O

O

OH OH O NH O HN

O O O NH O N

HN

O

O

O

NH H2N NH NH

HN N O O O N

O HOOCH N N HCOOH H H

O

N3

O

COOH

H N

O

O

O

HN

DIPEA room temperature

O O O NH O HN N

O

O O

OH OH O NH O HN

O O O NH O N

NH HN NH2

Scheme 1 Synthesis and 18F labeling of the N3-NT-PSMA heterodimer HO

HO

O

O HO

H 2N

N HN

NH

HO

HN

NH H 2N

NH

O

O O O O

NH

O O

+

O

O

N3

O

O

DMSO, DIPEA N O

room temperature

O

NH

NH2

O HO

N

N

H

O

N

H 2N

O

H

Scheme 2 Synthesis and

N H

O

NH

H 2N

HN O

O O

NH

N

O O

O NH

O O O

N

N H

H N HN

+

85 C, 15min

NH

H

H O

N

18

H N

F

NH2

HN

O

18F

HN

o

O

N H

N

NH

O

O O O

NH

O

HN

NH

O

N

O O

HN

HO

HN

F

O

N H N

O

18

N3

O

NH

O

N

N H

N

O

NH

labeling of the N3-NT monomer


O

O

N H

O

NH2

F

Page 5 of 20 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


O

NH2 O

COOH

+

O HOOC

H

N H

N3

O

O O

O

COOH O HOOC

N

N

O

N

H

H O

F

O

O

N COOH H H

+ NH

85oC, 15min

O HOOC

H

N H

H

H

N COOH H H

O 18

N H

N H H

O O

COOH

18

NH

O

room temperature

O

N COOH H H

N3

DMSO, DIPEA

N

O

O

Scheme 3 Synthesis and 18F labeling of the N3-PSMA monomer

Results Chemistry and Radiochemistry


F

O

O

N H

O


The N3-NT-PSMA heterodimer was synthesized by sequentially coupling NTR1 ligand (NT20.3) and PSMA ligand (Glu-urea-lys(Ahx)) to trifunctional linker N-(Azido-PEG3)-Nbis(PEG3-NHS ester). One of the two NHS ester groups react with NT first, leading to NTtrifunctional linker-NHS intermediate, unreacted trifunctional linkers and some decomposed NHS esters. Excess amount of PSMA ligand was then added and N3-NT-PSMA heterodimer was obtained with a yield of 44.3% based on NT20.3 after HPLC purification. Other impurities in final reaction mixtures may include N3-(PSMA)2 and N3-NT-COOH, which could be successfully removed to get N3-NT-PSMA heterodimer with 99% purity. The azide group in heterodimer was left for further radiolabeling. Similarly, N3-NT could be obtained at 85.7% yield and 99% purity. In brief, 18F-BCN was synthesized in 8% isolation yield based on our previous report28. Through strain promoted azide alkyne click reaction, the radiolabeling of the N3-NT-

PSMA heterodimer and N3-NT monomers are performed and the decay-corrected isolation yield was 39.5% and 34.1%, respectively, with radiochemical purity over 99% (Fig 1). The purity was double confirmed by isocratic HPLC using 32% acetonitrile/water 0.1% TFA as mobile phase (Fig S4 and S5). The identity of the product was confirmed by co-injection with the 19F compounds. The 18F-BCN-N3-PSMA was prepared as previously reported 28. The logP value of 18F-BCN-NT-PSMA

and 18F-BCN-NT was -1.06 ± 0.02 and -0.30 ± 0.02, respectively. The logP

of 18F-BCN-PSMA was -1.90 ± 0.01 which was consistent to the previously reported value28. Figure 1 HPLC profile of (a) 18F-BCN-NT-PSMA at radio channel, (b) 18F-BCN-NT-PSMA at 210nm


Page 6 of 20

Page 7 of 20 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


UV channel, (c) 19F-BCN-NT-PSMA at 210nm UV channel, (d) 18F-BCN-NT at radio channel, (e) 18F-BCN-NT

at 210nm UV channel, (f) 19F-BCN-NT at 210nm UV channel

In Vitro Cell Binding Assay The NTR1 binding affinity of 19F-BCN-NT-PSMA and 19F-BCN-NT was evaluated in PC-3 cells and compared with the parent peptide NT (8-13). As can be seen in Fig 2a, both compounds showed dose-dependent binding curve with IC50 value of 50.2nM for 19F-BCN-NTPSMA and 43.7nM for 19F-BCN-NT. These values demonstrated that the NT-PSMA heterodimer has slightly lower but still comparable NTR1 binding affinity compared with the corresponding monomer. For the PSMA binding moiety, Fig 2b showed that the 19F-BCN-NTPSMA had IC50 value of 156.4 nM whereas 19F-BCN-PSMA had IC50 value of 26.1 nM in LnCaP cells. The heterodimer had 6-fold higher IC50 value which indicated slightly reduced binding affinity than the corresponding monomer.

Figure 2 (a) Inhibition of 125I-NT (8-13) binding to NTR1 on PC-3 cells by 19F-BCN-NT and 19F-BCNNT-PSMA heterodimer (n=3, mean ± SD). (b) In vitro binding assay of 19F-BCN-PSMA and 19F-



BCN-NT-PSMA heterodimer (n=3, mean ± SD). Small Animal PET Imaging Studies To evaluate the dual receptor targeting efficiency of 18F-BCN-NT-PSMA in vivo, we performed static PET imaging studies in both NTR1_positive/PSMA_negative PC-3 tumor model and NTR1_negative/PSMA_positive LnCaP tumor model at 40min and 120min post injection. As shown in Fig 3, 18F-BCN-NT-PSMA showed reasonable tumor uptake at 40min post injection in both tumor models with uptake of 1.4 ± 0.3 %ID/g in PC-3 and 1.3 ± 0.2 %ID/g in LnCaP, respectively. The tracer was then cleared through renal pathway and the tumor uptake was reduced to 0.5 ± 0.2 %ID/g in PC-3 and 0.3 ± 0.1 %ID/g in LnCaP at 120min post injection. The specificity of each targeting moiety was confirmed by blocking studies where either excess amount of NT peptide was coinjected in PC-3 tumor models or excess amount of PSMA ligand was coinjected in LnCaP models. Both blocking groups showed significant decrease of tumor uptake at 40min post injection (Fig S6). As for the corresponding monomers, 18F-BCN-NT only showed apparent tumor uptake in NTR1_positive PC-3 tumor xenografts with 1.2 ± 0.3 %ID/g at 40min post injection. The NTR1_negative/PSMA_positive LnCaP tumor did not have obvious tracer uptake (Fig 4). 18F-BCN-PSMA on the other hand, showed visible uptake in LnCap tumors but undetectable uptake in NTR1_positive/PSMA_negative PC-3 tumors (Fig 5) similar to previous report28. 18F-BCN-NT-PSMA was mainly cleared through renal pathway, similar to the two monomers. However, the absolute kidney uptake number was significantly reduced for heterodimer, compared with PSMA monomer in both tumor models, which could be partially caused by the decreased water solubility (The logP value of 18F-BCN-NT-PSMA and 18F-BCNPSMA was -1.06 ± 0.02 and -1.90 ± 0.01, respectively). The heterodimer has comparable liver or muscle uptake with monomers at both time points. The quantitative uptake of other major organs was shown in Fig 6.


Page 8 of 20

Page 9 of 20 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Figure 3 Representative PET/CT images of 18F-BCN-NT-PSMA heterodimer in PC-3 tumor models at (a) 40min and (b) 120min post injection. Representative PET/CT images of 18F-BCN-NT-PSMA heterodimer in LnCaP tumor models at (c) 40min and (d) 120min post injection. Orange circled area is tumor.



Figure 4 Representative PET/CT images of 18F-BCN-NT in PC-3 tumor models at (a) 40min and (b) 120min post injection. Representative PET/CT images of 18F-BCN-NT in LnCaP tumor models at (c) 40min and (d) 120min post injection. Orange circled area is tumor


Page 10 of 20

Page 11 of 20 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Figure 5 Representative PET/CT images of 18F-BCN-PSMA in PC-3 tumor models at (a) 40min and (b) 120min post injection. Representative PET/CT images of 18F-BCN-PSMA in LnCaP tumor models at (c) 40min and (d) 120min post injection. Orange circled area is tumor



Figure 6 PET derived quantitative uptake of BCN-NT-PSMA heterodimer and corresponding monomers in (a) PC-3 at 40min, (b) PC-3 at 120min, (c) LnCaP at 40min and (d) LnCaP at 120min

Discussion Prostate cancer is the most common cancer affecting men in the United States2. Although incidence has leveled off in recent years, the American Cancer Society estimates that approximately 181,000 men were diagnosed with prostate cancer in 201629. Approximately 60% of incident prostate cancer cases are diagnosed at ≥ 65 years of age30. The initial treatment and subsequent monitoring of these large numbers of prostate cancer cases places a burden on U.S. health care systems. Prevalence based treatment costs for 2010 alone have been estimated at $11.9 billion31, 32 The current standard for prostate cancer screening involves a digital rectal examination and the determination of prostate-specific antigen (PSA) levels in patient blood samples followed


Page 12 of 20

Page 13 of 20 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


by biopsy confirmation33. However, high PSA level has been observed in benign prostatic hyperplasia (BPH), and patient with low PSA value could have prostate cancer metastases 34. Clearly, developing new biomarkers for accurate prostate cancer diagnosis is still in great need. Recently, PSMA has attracted extensive attention due to its great potential in detecting metastasis of recurrent prostate cancer with high quality imaging results10. However, prostate cancer is a highly heterogeneous disease, and some prostate metastases could have low or negative PSMA expression based on recent studies 35. Clearly, the heterogeneity of prostate cancer needs to be addressed when developing novel prognosis and therapeutic options for prostate cancer. One strategy to improve the sensitivity of an imaging agent is to add another targeting moiety and combine the two specific targeting agents into one dual-targeting molecule. Here we utilized a trifunctional linker with two N-hydroxysuccinimide groups for targeting moiety conjugation and one azide branch for radiolabeling (Scheme 1). Compared with some previous studies on heterodimer synthesis, our method did not involve isomers which may form using asymmetric linkers. Furthermore, by introducing azide group for radiolabeling, strain-promoted azide-alkyne reaction could be easily applied. This would improve the radiolabeling yield and make the synthesis procedure straightforward as long as the ligands to be screened bear a N3 group. We first evaluated the in vitro cell binding affinity of the heterodimer. The NTR1 targeting moiety retained its binding property compared with the corresponding monomer whereas the PSMA moiety showed reduced binding affinity. The reduced binding affinity for the PSMA moiety might be caused by the introduction of a relatively large NT peptide motif. The NT peptide accounted for roughly half of the molecular weight of 19F-BCN-NT-PSMA while PSMA ligand only contributed to 1/10. In fact, the binding affinity did not alter much between NT monomer and heterodimer but showed large decrease for heterodimer compared with PSMA monomer. This was further confirmed by microPET imaging studies. Although the heterodimer accumulated in both NTR1 and PMSA positive tumor models, the heterodimer uptake in LnCaP tumor models was less than PSMA monomer which may partially due to the reduced binding affinity for the PSMA moiety. The specificity was confirmed by performing imaging studies of monomers in both NTR1 positive/PSMA negative and NTR1 negative/PSMA positive tumor xenografts. Our results showed that monomers could only be observed in either one of the tumor



models, which indicated the specificity of each targeting moiety. However, the heterodimer tracer could successfully visualize both tumor models which implied it could be served as a diagnostic tool in heterogeneous prostate cancer. Another impact needs to be considered when studying heterodimer is the pharmacokinetic properties compared with each specific monomer. The heterodimers should at least show comparable pharmacokinetic properties with the separate application of both monomer compounds. In our scenario, the heterodimer showed similar tumor uptake with the corresponding monomer N3-NT in NTR1 positive/PSMA negative PC-3 tumor xenografts. Normal organs distribution such as liver, kidney and muscles are also comparable. Regarding the comparison between heterodimer and N3-PSMA monomer, both compounds showed similar liver uptake but the heterodimer exhibit significantly reduced kidney uptake. Since Glu-urealys(Ahx) was much more hydrophilic than NT peptide, the combination of the two moieties in heterodimer may increase the lipophilicity and thus reduce the kidney uptake. However, we do like to point out that all the three tracers showed high signals from abdomen area thus the uptake reduction in kidney did not change too much on the tumor to background contrast. Compared with other commonly used PSMA PET probes such as 68Ga-PSMA11, 18F-DCFPyL and 18FPSMA-1007, the LnCaP tumor uptake of 18F-BCN-NT-PSMA heterodimer was lower along with reduced uptake in other major organs such as liver and kidney36-38. However, the integration of NTR1 targeting moiety could not only increase prostate cancer sensitivity, but also combine two NTR1 and PSMA PET scans into one, which would potentially reduce the radiation exposure to patients. This dual targeting approach could also provide a treatment option that would target more cancer lesions once the heterodimer is loaded with therapeutic moieties. In addition to guiding radiation therapy after detecting the lesions, therapeutic-radionuclide or chemo-drugs could be conjugated with NT-PSMA heterodimer for targeted delivery to prostate cancer. The 18F labeled heterodimer could be used as a companion diagnosis agent. The dual targeting rationale was further supported by the observation that PSMA negative prostate cancer (for example PC-3) could have high NTR1 expression, suggesting the complementary role of these two targets. We do like to point out that these agents would need to be further optimized before clinical application. The absolute tumor uptake for current construct is still low and may not meet therapeutic requirement. Our future design would focus on increasing absolute tumor uptake and


Page 14 of 20

Page 15 of 20 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


reducing the uptake in normal tissues.

Conclusion We have developed a heterodimeric peptide that binds to two distinct antigens related to prostate cancer: neurotensin receptor1 and prostate-specific membrane antigen. In vitro and in vivo experiments demonstrated PSMA-NT heterodimer has promising bispecific targeting capability, which would benefit prostate cancer imaging by enhancing the sensitivity. In addition to the imaging applications demonstrated in this study, the agent also holds the great potential on the treatment of heterogeneous prostate cancer.

Materials and Methods All chemicals obtained from commercial source were used without further purification. NT peptide Lys-NT20.3 was purchased from C.S. Bio (CA,USA) and PSMA ligand Glu-urealys(Ahx) was purchased from FutureChem (Seoul, Korea). A Kintex 5μ C18 column (250mm x 4.6mm) was used on analytical reversed-phase HPLC and Gemini 5μ C18 column (250mm x 10mm) was used for semi-prep reversed-phase HPLC. Solvent A was 0.1% TFA in water and solvent B was 0.1% TFA in acetonitrile. The flow was 3mL/min HPLC program A: The mobile phase was 95% solvent A and 5% solvent B from 0 to 2min and jumped to 70% solvent A and 30% solvent B at 4min. Then the gradient went to 60% solvent A and 40% solvent B at 24min. HPLC program B: The mobile phase was 95% solvent A and 5% solvent B from 0 to 2min and ramped to 5% solvent A and 95% solvent B in 20min. Preparation of N3-NT-PSMA heterodimer N-(Azido-PEG3)-N-bis(PEG3-NHS ester) was purchased from Broadpharm (CA, USA). To a solution of N-(Azido-PEG3)-N-bis(PEG3-NHS ester) (2.5 mg, 3.1 μmol) in 50 μL of anhydrous dimethyl sulfoxide (DMSO), 0.3 eq of Lys-NT20.3 (1.0 mg, 0.9 μmol) was added. After adding 7.4mg (57.4 μmol) of diisopropylethyl amine, the mixture was incubated at room temperature for 2h. Without purification, 1.5 eq of Glu-urea-lys(Ahx) (1.5mg, 4.7 μmol) was added and the reaction was stirred for another 2h. The desired product was isolated by semi-prep HPLC using HPLC program A. Preparation of N3-NT and N3-PSMA



Azido-PEG-NHS (1.0 mg, 3.3 μmol) was dissolved in 50 μL of anhydrous DMSO. 0.3 eq of Lys-NT20.3 (1.1 mg, 1.0 μmol) was added to the solution and incubated at room temperature for 2h. The product was isolated with semi-prep HPLC using HPLC program B. N3-PSMA was synthesized according to our previously reported protocol28. Radiochemistry 18F-bicyclo[6.1.0]nonyne (18F-BCN)

was synthesized according to our previously

reported protocol28. To prepare corresponding PET agents, 50 μg of N3-NT-PSMA, N3-NT or N3-PSMA was added to the solution containing 185 MBq of 18F-BCN respectfully and incubated at 80oC for 15min. The mixture was loaded on HPLC for further analysis and purification. The desired product collected from HPLC was reconstituted in 1X PBS and rotary evaporated to remove the organic solvent before subjected to further in vivo experiments. Octanol/Water partition coefﬁcient were measured based on literature report28. Cell Lines and Animal Models Prostate cancer cell line PC-3 and LnCaP were obtained from the Tissue Culture Facility of UNC Lineberger Cancer Center. Cell culture was performed as described 39. Animal procedures were performed according to a protocol approved by the University of North Carolina Institutional Animal Care and Use Committee. In brief, PC-3 xenograft model was established by subcutaneously inoculation of 5×106 PC-3 cells resuspended in 100 µL PBS into 4- to 6-wk-old male athymic mice (BALB/nu/nu); while LnCaP xenografts were established by subcutaneous inoculation cells 100 µL mixture of Matrigel and 5×106 LNCaP cells at 1:1 volume into NSG mice. In Vitro Cell Binding Assay The in vitro cell binding assay towards NTR1 and PSMA were performed according to previously reported protocol28, 40. Small Animal PET Imaging Studies The PET scan and analysis were performed as previously reported28. PC-3 or LnCaP tumor model mouse was injected with either 18F-BCN-N3-NT-PSMA, 18F-BCN-N3-NT or 18F-BCN-N3PSMA and subjected to static PET scan at 40min and 120min post injection. Statistical Analysis Quantitative data are expressed as mean ± SD. Means were compared using 1-way ANOVA and the Student t test. P

Development of bispecific NT-PSMA heterodimer for prostate cancer

Recommend Documents